scholarly journals Hair growth effect of traditional Chinese medicine BeauTop on androgenetic alopecia patients: A randomized double-blind placebo-controlled clinical trial

2016 ◽  
Vol 13 (1) ◽  
pp. 194-202 ◽  
Author(s):  
Chien-Ying Lee ◽  
Cheng-Chung Wei ◽  
Min-Chien Yu ◽  
Ching-Che Lin ◽  
Shuenn-Jyi Sheu ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Hair Growth ◽  
Growth Effect ◽  
Androgenetic Alopecia ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

Effect of a sphingolipid‐mimetic compound on the promotion of hair growth: A randomized, double‐blind, placebo‐controlled clinical trial

2019 ◽  
Vol 19 (7) ◽  
pp. 1715-1722 ◽  
Author(s):  
Weon Ju Lee ◽  
Chihyeon Sohng ◽  
Jun Young Kim ◽  
Kyung Duck Park ◽  
Yong Hyun Jang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Hair Growth ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Mimetic Compound

scholarly journals Acute Efficacy of a Traditional Chinese Medicine for Treatment of Frequent Premature Ventricular Contractions in Patients with Concomitant Sinus Bradycardia: Results from a Double-Blind, Placebo-Controlled, Multicentre, Randomized Clinical Trial

2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Fengxiang Zhang ◽  
Jiangang Zou ◽  
Hao Yu ◽  
Xiaorong Li ◽  
Pipin Kojodjojo ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Randomized Clinical Trial ◽  
Beta Blockers ◽  
Sinus Bradycardia ◽  
Antiarrhythmic Therapy ◽  
Double Blind ◽  
Premature Ventricular Contractions ◽  
Double Blind Placebo

Pharmacological antiarrhythmic therapy such as beta-blockers in patients with frequent premature ventricular contractions (PVCs) and concomitant bradycardia is challenging. A traditional Chinese medicine, Shensong Yangxin (SSYX), has been effective in treatment of frequent PVCs and sinus bradycardia (SB) in separate patient cohorts. This double-blind, placebo-controlled, multicentre, randomized clinical trial investigates the acute efficacy of SSYX in reducing PVCs burden in patients with concomitant SB. Patients with symptomatic, frequent PVCs, and SB, defined as mean heart rate (MHR) of 45 to 59 beats per min (bpm), were recruited at 33 medical centres in mainland China and randomly assigned by computer to either SSYX or matching placebo for eight weeks. Patients, investigators, and trial personnel were masked to treatment allocation. Primary endpoints were changes in PVCs burden and MHR as assessed by 24-hour Holter monitoring relative to baseline. Secondary efficacy endpoints were subjective symptom score, ECG, and biochemical parameters. Analysis was based on intention-to-treat principles. 333 patients were randomized, of which 166 received SSYX and 167 placebo. Baseline characteristics did not differ. SSYX reduced PVCs burden by 68.2% (p < 0.001) and increased MHR by 10.9% (p < 0.001) compared to 32.2% and 4.7%, respectively, in the placebo group. SSYX group experienced greater symptomatic improvement (p < 0.001). No differences in reported adverse events were seen (20 versus 23). SSYX is an effective antiarrhythmic therapy for symptomatic, frequent PVCs uniquely suited patients with concomitant SB. Clinical trial number was NCT01750775.

scholarly journals A Clinical Trial to Investigate the Effect of Cynatine HNS on Hair and Nail Parameters

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Christina Beer ◽  
Simon Wood ◽  
Robert H. Veghte
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Amino Acid ◽  
Hair Loss ◽  
Hair Growth ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
End Points ◽  
Double Blind Placebo ◽  
New Novel

Objective. A new, novel product, Cynatine HNS, was evaluated for its effects as a supplement for improving various aspects of hair and nails in a randomized, double-blind, placebo-controlled clinical trial.Methods. A total of 50 females were included and randomized into two groups. The active group (n=25) received 2 capsules containing Cynatine HNS, comprised of Cynatine brand keratin (500 mg) plus vitamins and minerals, per day, and the placebo group (n=25) received 2 identical capsules of maltodextrin per day for 90 days. End points for hair loss, hair growth, hair strength, amino acid composition, and hair luster were measured. End points were also measured for nail strength and the appearance of nails.Results. The results show that subjects taking Cynatine HNS showed statistically significant improvements in their hair and nails when compared to placebo.Conclusion. Cynatine HNS is an effective supplement for improving hair and nails in 90 days or less. EudraCT number is 2014-002645-22.

scholarly journals The Efficacy of the Traditional Chinese Medicine Yiqi-Huayu-Tongsui Granule in Treating Mild or Moderate Cervical Spondylotic Myelopathy: A Randomized, Double-blind, Placebo-controlled Clinical Trial

2020 ◽  
Author(s):  
Chongqing Xu ◽  
Xiaoning Zhou ◽  
Zhengyi Tong ◽  
Junming Ma ◽  
Jie Ye ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Neck Pain ◽  
Cervical Spondylotic Myelopathy ◽  
Motor Dysfunction ◽  
Controlled Clinical Trial ◽  
Sensory Disturbance ◽  
Double Blind ◽  
Outcome Measurements

Abstract Background: Neck pain, sensory disturbance and motor dysfunction in most patients suffered cervical spondylotic myelopathy. However, some conservative treatments are limited by their modest effectiveness. In the other hand, surgical treatment is necessary when symptoms are refractory to conservative treatments and neurological function of the patients has deteriorated. Many patients use complementary and alternative medicine, including traditional Chinese medicine, to address their symptoms. The purpose of the present study is to examine effectiveness and safety of Yiqi-Huayu-Tongsui granule, a compound traditional Chinese herbal medicine, on symptoms in patients with mild or moderate cervical spondylotic myelopathy.Methods/Design: A randomized, double blinded, placebo-controlled clinical trial to evaluate the efficacy and safety of Yiqi-Huayu-Tongsui granule is proposed. 72 patients in Longhua Hospital with the diagnosis of mild or moderate cervical spondylotic myelopathy will be randomly allocated into two groups, and treated with Yiqi-Huayu-Tongsui granule or placebo. The prescription of the trial drugs (Yiqi-Huayu-Tongsui granule / placebo) is 20 grams twice a day for 3 months. The primary outcome measurements include VAS, JOA and NDI score. The secondary outcome measurements are electromyogram and Pfirrmann classification.Discussion: Yiqi-Huayu-Tongsui granule has been established and applied in Longhua Hospital for many years. As it has a potential benefit in treating mild or moderate cervical spondylotic myelopathy, we designed a double-blind, prospective, randomized controlled trial and would like to publish the results and conclusions later. If Yiqi-Huayu-Tongsui granule can alleviate neck pain, sensory disturbance, and even motor dysfunction without adverse effects, it may be a unique strategy for the treatment of mild or moderate cervical spondylotic myelopathy.Trial registration: Chinese Clinical Trial Registry ID: ChiCTR1900028192. Registered 15 December 2019, http://www.chictr.org.cn/edit.aspx?pid=46913&htm=4

Sign in / Sign up

Export Citation Format

Share Document